Monday, 26 October 2026European Markets

ADYEN Stock Went Down By Over 17% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of ADYEN (AEX-Index: ADYEN.AS) fell by a staggering 17.28% in 5 sessions from 1625 € to 1,344.20 € at 01:09 EST on Friday, after four successive sessions in a row of losses. AEX-Index is jumping 1.16% to 757.05 €, following the last session's downward trend.

About ADYEN

Adyen N.V. operates a payments platform in Europe, the Middle East, Africa, North America, the Asia Pacific, Latin America. The company's platform integrates payments stack that include gateway, risk management, processing, issuing, acquiring, and settlement services. It offers a back-end infrastructure for authorizing payments across merchants' sales channels, as well as online, mobile, in-store, and APIs; and data insights. The company's platform services a range of merchants across various verticals, connecting them directly to Visa, Mastercard, and other payment methods. Adyen N.V. was incorporated in 2006 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, ADYEN has a trailing twelve months EPS of 16.72 €.

PE Ratio

ADYEN has a trailing twelve months price to earnings ratio of 80.39. Meaning, the purchaser of the share is investing 80.39 € for every euro of annual earnings.

Volatility

ADYEN's last week, last month's, and last quarter's current intraday variation average was a negative 2.11%, a positive 0.32%, and a positive 2.41%.

ADYEN's highest amplitude of average volatility was 2.11% (last week), 2.55% (last month), and 2.41% (last quarter).

More news about ADYEN (ADYEN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com